Pangenomic Health Inc.
NARA.CN
Canadian Securities Exchange0.33
CAD
-0.04
- -
Pangenomic Health Inc.
NARA.CN
(Canadian Securities Exchange)
Recent
price
0.33
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Pangenomic Health Inc. (CSE:NARA) operates as a precision health company focused on digital platforms that deliver personalized, evidence-based natural remedies and wellness solutions for mental and physical health; its core offerings include the Nara app, a telehealth mental health application providing curated natural remedies, personalized insights, and evidence-backed resources with Nara App V2 forthcoming; Mindleap, a holistic wellness app offering audio content, blogs, mental health tracking, and professional services; MUJN Diagnostics, a clinical decision support platform featuring point-of-care biomarker testing including Vitamin D and BDNF tests, symptom tracking, automated trend analysis, and patient-practitioner connectivity targeted at dental implants and brain health; AGENTA Health, an AI-driven agent crafting tailored supplement and longevity plans; the PlantGx platform enabling practitioners to access consumer data for optimizing natural remedies; and the Nustasis AI Platform alongside NaraCare.AI with recent DNA testing program expansion. The company, founded in 2015 and headquartered in Vancouver, British Columbia, Canada, primarily serves consumers and healthcare practitioners in North America through self-care digital tools that complement conventional medicine with plant-based and genomic-informed options; it functions as a public benefit corporation emphasizing accessibility, individuality, and evidence-based natural wellness. Recent developments encompass the acquisition of Mindleap Health Inc. from Mydecine Innovations Group Inc. in November 2022; listing on the AQSE Growth Market in London, UK; a non-binding letter of intent with Crescita Capital for a $5 million equity drawdown facility; signing of a non-binding letter of intent for an exclusive license of the CyberPatient AI medical education platform; subsidiary MUJN Diagnostics launching point-of-care Vitamin D tests for the dental implant industry, introducing Vitamin D health assessments, achieving first BDNF biomarker test sales, and partnering with Hemex Health and Circle Innovation for brain health diagnostics development; debut of the NARA website, visual identity, and natural wellness e-commerce store; expansion of the NaraCare.AI platform via a DNA testing program; closure of a private placement for $750,000; board and management changes; completion of withdrawal from AQSE; and application for a management cease trade order due to late filing of 2024 audited financial statements.